NeoMatrix Therapeutics is focused on developing innovative therapies for burn treatment, utilizing a pipeline that includes several promising candidates. Their lead product, NMT-cP12, is currently in Phase 2 clinical trials and has received Orphan Drug and Fast Track designations, indicating its potential to address unmet medical needs in burn care. Additionally, the company is advancing NMT-cNP8, which is being developed in both intravenous and topical formulations. The intravenous version of NMT-cNP8 is in the Pre-IND stage, while the topical formulation is still in the preclinical phase, showcasing the company's commitment to exploring multiple delivery methods for effective treatment.

The technologies employed by NeoMatrix Therapeutics are centered around their proprietary formulations aimed at enhancing healing and recovery for burn patients. Their research emphasizes the development of targeted therapies that can significantly improve patient outcomes. By focusing on both intravenous and topical applications, NeoMatrix Therapeutics aims to provide versatile treatment options that cater to different clinical scenarios, thereby addressing a wide range of indications related to burn injuries.

United States

NeoMatrix Therapeutics, Inc. is a clinical-stage company dedicated to discovering and developing novel therapeutic agents for the treatment of serious burn injuries. They focus on developing bioactive peptides that prevent injury progression and rescue tissue from further damage.

NeoMatrix Therapeutics

Company Details